Ablynx is a biopharmaceutical company dedicated to creating new antibody-based medicines called Nanobodies which will make a real difference to society. Ablynx has currently over 400 people working on the development of Nanobodies for the treatment of a wide range of diseases, including inflammation, haematology, respiratory disease, immuno-oncology and oncology.
LENSA generates certain information provided on this website by compiling and analyzing publicly available data and data from employees/former employees. All company names are the registered trademarks of their original owners. The use of any trade name or trademark does not imply any association with the third-party company. None of the information provided is endorsed in any way by any of the companies mentioned. We do not guarantee the accuracy, currency, or suitability of this information (including regarding demographics or salary estimate) and you are responsible for how you use it. ALL INFORMATION IS PROVIDED “AS IS” AND “WITH ALL FAULTS”. We are not responsible for nor endorse third party content on our website. If you notice any inaccurate information or information you think is proprietary you can email us at [email protected]. See our Terms and Conditions and Community Guidelines for more information.
